YM Biosciences Licenses Monoclonal Antibody, Nimotuzumab, to Daiichi Pharmaceutical for Japan
02-Aug-2006 -
YM BioSciences Inc. announced that its majority owned subsidiary, CIMYM BioSciences Inc., has licensed development and marketing rights in Japan for its anti-EGFR humanized antibody, nimotuzumab, to Daiichi Pharmaceutical Co., Ltd. (a wholly owned subsidiary of DAIICHI SANKYO COMPANY, ...
colorectal cancer
Daiichi Sankyo
diarrhea
+8